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Paul Moody,[a, b] Mark. E. B. Smith,[a] Chris P. Ryan,[a] Vijay Chudasama,[a] James R. Baker,*[a] Justin Molloy,*[b] and
Stephen Caddick*[a]
Bromomaleimides have recently been shown to act
as small, versatile scaffolds for the controlled assem-
bly of thiolated biomolecules.[1–4] They present three
points of chemical attachment, thereby allowing the
modular construction of multifunctional bioconju-
gates. The bromomaleimide scaffold introduces no
new chiral centres to the final construct and, in con-
trast to disulfide linkages, bromomaleimides can be
used to link two unactivated biomolecules of equal
concentration with minimal formation of homodi-
meric side products.[2] Bromomaleimide adducts
have been shown to dissociate in vitro in the pres-
ence of reducing agents to liberate the composite
thiols.[2] The cytoplasm of cells contains 1–10 mm re-
duced glutathione,[5] thus raising the possibility that
bromomaleimide conjugates could be cleavable in
vivo. If this could be demonstrated, then a number
of medical and academic applications can be envis-
aged that combine in vivo cleavage with multiple
points of scaffold attachment. However, a number of
factors might inhibit cytoplasmic cleavage, in partic-
ular pH-dependant[3] and protease-catalysed amide
bond hydrolysis. Using a series of bromomaleimide-
linked green fluorescent protein (GFP)–rhodamine
conjugates, designed as FRET pairs, we demonstrate
herein that bromomaleimide-linked bioconjugates
cleave in the cytoplasm of mammalian cells.
Rhodamine–maleimide derivatives 4–6 were gen-
erated by condensation of the relevant maleic anhy-
dride with a common intermediate, 3 (Scheme 1).
The two native cysteines in wild-type superfolder
GFP,[6] C48 and C70, were shown to be inaccessible
to maleimide functionalisation under our reaction
conditions (see Section 4 in the Supporting Informa-
tion). A GFP with a free, accessible thiol close to its
fluorophore (GFP-SH) was generated by introducing
an S147C mutation into superfolder GFP. The mutat-
ed GFP-SH produces a similar emission spectrum to
wild-type superfolder GFP. The folded protein was shown to be
resistant to disulfide-mediated dimerisation, thus allowing
GFP-SH to be conjugated to maleimides without the need for
reducing agents (see Section 5 in the Supporting Information).
Compounds 4–6 were attached to GFP-SH as described in
the Supporting Information, Section 5. Stoichiometric addition
of rhodamine–maleimide was confirmed by mass spectrometry.
The emission spectra of the resultant constructs 7–10 are illus-
trated in Figure 1. In each case, addition of rhodamine–malei-
mide was shown to result in efficient quenching of GFP fluo-
rescence. Little increase in emission at 590 nm was seen.
Cleavage of compounds 7–10 by a physiologically relevant
concentration of reduced glutathione (1 mm) was monitored
in vitro by dual-channel measurement of the GFP and rhoda-
Scheme 1. Synthesis of rhodamine-bromomaleimides. a) (COCl)2, 20 8C, 15 h; b) piperidin-
4-yl carbamic acid tert-butyl ester (10.4 equiv), CsCO3 (10.4 equiv), CH2Cl2, 20 8C, 24 h,
71% (2 steps) ; c) TFA/CH2Cl2 (1:1), 20 8C, 5 h, 100%; d) maleic anhydride (1.4 equiv),
AcOH, 120 8C, 5 h, 40%; e) bromomaleic anhydride (1.4 equiv), AcOH, 120 8C, 5 h, 66%;
f) dibromomaleic anhydride (1.4 equiv), AcOH, 120 8C, 5 h, 66%.
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mine emission intensities upon excitation of GFP at 494 nm
(Figure 2).
As expected, the GFP emission intensity associated with 7
did not change upon addition of glutathione, whereas that
associated with 8–10 increased. The data fitted well to a single
exponential increase in free GFP concentration over time, sug-
gesting first-order kinetics with respect to conjugates 8–10
under these conditions. Rate constants of 1.9 s1 for 8, 26 s1
for 9 and 2.8 s1 for 10 were calculated.
For compounds 7–9, little change in apparent rhodamine
emission (590 nm) was seen during the experiments. For com-
pound 10, a decrease in rhodamine emission was observed;
this suggesting that FRET is disrupted. The efficient quenching
of GFP fluorescence allowed us to use the ratio of GFP/rhoda-
mine emission intensities as a quantitative measure of cleav-
age during subsequent microinjection experiments. Cleavage
of constructs 8–10 was also confirmed by mass spectrometry
under analogous reaction conditions (see Section 7 in the Sup-
porting Information).
Cleavage of constructs 8–10 in human cells was demonstrat-
ed by microinjection into live, cultured HeLa cells, followed by
time-lapse fluorescence microscopy. GFP was excited by using
a 450–490 nm filter, and GFP and rhodamine emission were
measured simultaneously by using an image splitter that con-
tained GFP (500–550 nm) and rhodamine (575–630 nm) emis-
sion filters (Figures 3 and 4).
In each case, both the absolute GFP intensity post-microin-
jection (see Section 8 in the Supporting Information) and ratio-
metric data fitted well to a single exponential increase, thus
showing that bromomaleimide-linked constructs are cleaved in
cells. The order of reactivity is the same as that observed in
vitro (see Section 9 in the Supporting Information); this sug-
gests that the mechanism of cleavage in cells is the same as
the mechanism in vitro. The ratio of GFP/rhodamine emission
intensity at equilibrium is consistent with the ratio observed
Figure 1. Emission spectra of superfolder GFP, the mutant GFP-SH and the
rhodamine conjugates; compounds 7–9 (0.85 mm), compound 10 (0.425 mm ;
lex=494 nm).
Figure 2. In vitro cleavage of the rhodamine–GFP conjugates. Glutathione
(1 mm) was added to compounds A) 7, B) 8, C) 9 (0.85 mm each) and D) 10
(0.43 mm). GFP was excited at 494 nm; GFP emission (515 nm, green) and
rhodamine emission (590 nm, red) were measured simultaneously.
Figure 3. In-cell cleavage of compound 9 following microinjection into HeLa
cells. The image was cast onto the upper and lower halves of the CCD
sensor by using an image splitter (Optical Insights). Top: GFP emission,
bottom: rhodamine emission. A) DIC image immediately before injection.
B) Fluorescence image immediately after injection. C) Fluorescence image
10 min after cleavage. Scale bars=5.0 mm.
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for cleaved constructs deposited directly onto glass slides (see
Section 10 in the Supporting Information). This suggests that
complete cleavage of the bromomaleimide linkages occurs in
HeLa cells. Disassembly of the fully conjugated dibromomalei-
mide (10) was also successfully demonstrated in COS-7 cells
(see Section 8 in the Supporting Information), thus highlight-
ing that observed in cell cleavage is not restricted to HeLa
cells.
In summary, we have demonstrated that bromomaleimide-
linked conjugates can be cleaved with first-order kinetics both
in vitro and in cells. Dibromomaleimide derivatives (9 and 10)
cleave at a faster rate than monobromomaleimide construct 8.
Maleimide construct 7 is stable to thiol-promoted cleavage.
We envisage that bromomaleimides have potential as scaffolds
for the synthesis of a variety of multifunctional reagents. We
believe that the FRET construct 9 has a specific application in
the screening of attached thiolated cell-penetrating structures
capable of successfully delivering protein cargo to the cyto-
plasm. More broadly, we believe that bromomaleimide scaf-
folds provide a potential core structure for the facile and versa-
tile construction of targeted therapeutics that will cleave to re-
lease their cargo once internalised into the cytoplasm. We shall
report on the further development and application of this
methodology in due course.
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Figure 4. In-cell cleavage of compounds 7–10 in HeLa cells. The GFP/rhoda-
mine emission ratio and exponential fits were calculated as described in the
Supporting Information.
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